Obstructive Lung Diseases: Airways 4 |

Effectiveness of Omalizumab Treatment in Asthma-COPD Overlap Syndrome FREE TO VIEW

Sibel Atis Nayci, MD; Eylem Ozgur, MD; Esin Tastekin, MD; Cengiz Ozge, MD
Author and Funding Information

Mersin University, Mersin, Turkey

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;150(4_S):867A. doi:10.1016/j.chest.2016.08.967
Text Size: A A A
Published online


SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM

PURPOSE: Omalizumab is indicated for treatment of patients with severe allergic asthma and well defined omalizumab efficacy in this patients, but there are no study regarding effectiveness of omalizumab in patients with Asthma-COPD Overlap Syndrome (ACOS) . ACOS is a syndrome characterized by reversible but persistant airflow limitation which has some features of both asthma and COPD. Frequent and severe exacerbations and related hospitalization are common in ACOS. We aimed to describe our experience with the clinical and functional effectiveness of the omalizumab treatment in patients with ACOS.

METHODS: This study was single-centre, prospective and observational. Six patients with ACOS were included (3 female and 3 male, age range 37-64 year). Clinical and functional data were collected at three time points: at baseline, after 4 and 12 months. Effectiveness outcomes included spirometry, systemic glucocorticosteroid (sGCS) use, short acting beta2agonist use (SABA), emergency room (ER) visits and hospitalizations for severe exacerbations.

RESULTS: Subjects were with the following mean values: mean duration of diseases 18.3±6.74 years, Total IgE serum levels: 414.5±161.1 U/mL; FEV1/FVC: 53.1±6.98 %; FEV1 47.5±6.95 %. The exacerbation rate reduced significantly from 19.66±8.57/y (mean ± SD) to 3±3.09, and the hospitalization rate reduced from 1.16±0.98/y to 0.16±0.4 at 12 months (p=0.002 and p=0.034,respectively). After omalizumab treatment was initiated, the patients' mean oral corticosteroid dosage significantly decreased (p=0.001). In two patients, steroid treatment was stopped. We did not observe significant change in FEV1 values at 4 months, however, it improves significantly following 12 months (p<0.05). Four of the patients (66.7%) responded perfectly, and two (33.3%) partially responded to treatment.

CONCLUSIONS: Omalizumab provided a clinically important reduction in exacerbations and steroid requirement, and improved symptoms and pulmonary function parameters in patients with ACOS.

CLINICAL IMPLICATIONS: Although this is a small sample of the population, omalizumab may be an alternative therapy for ACOS who fail to respond to Global Initiative for Asthma/ Global Obstructive Lund Disease treatment recommendations.

DISCLOSURE: The following authors have nothing to disclose: Sibel Atis Nayci, Eylem Ozgur, Esin Tastekin, Cengiz Ozge

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543